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activation and impaired bone mineral density in
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Background: HIV-infected patients display an increased and early incidence of osteopenia/osteoporosis. We
investigated whether bone metabolism disorders in HIV-infected patients are related to immune hyperactivation
and premature immune senescence.
Methods: Bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry (DXA): low BMD (LBMD) was
defined as T-score or z-score < −1. CD4+/CD8+ phenotype (CD38/HLA-DR, CD127, CD28/CD57), and circulating IL-7,
TNF-α, RANKL, OPG were measured. The variables with p < .05 were evaluated by multivariate logistic regression.
Results: 78 patients were enrolled: 55 were LBMD. LBMD patients showed increased activated HDLADR + CD4+ and
CD8+ (p = .03 and p = .002, respectively). Interestingly, no differences in senescent CD28-CD57 + CD4+/CD8+ T-cells
were observed between groups. However, LBMD patients displayed a decreased CD4 + CD28- phenotype (p = .04) at the
advantage of the CD28+ pool (p = .03), possibly reflecting heightened apoptosis of highly differentiated CD28-negative
cells.
Activated HLADR + CD4+/CD8+ and CD28 + CD4+ cells were independently associated with impaired BMD (AOR = 1.08
for each additional HLADR + CD4+ percentage higher; CI 95%,1.01-1.15; p = .02; AOR = 1.07 for each additional HLADR +
CD8+ percentage higher; CI 95%,1.01-1.11; p = .01; AOR = 1.06 for each additional CD28 + CD4+ percentage higher; CI
95%,1.0-1.13; p = .05).
Conclusions: Heightened T-cell activation in HIV-infected patients independently predicts BMD disorders, suggesting a
critical role of immune activation in the pathogenesis of osteopenia/osteoporosis, even in patients achieving full viral
suppression with HAART.
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HIV-infected patients are characterized by a high preva-
lence of osteopenia and osteoporosis [1] that may con-
tribute to an increased risk of pathologic fractures [2].
As clinicians who manage osteopenia/osteoporosis in
HIV infection, we should propose screening programs
and identify preventive clinical approaches. In this con-
text, a broad comprehension of the pathogenetic
mechanisms of bone mineral density (BMD) disorders in* Correspondence: giulia.marchetti@unimi.it
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reproduction in any medium, provided the orHIV/AIDS and a clear definition of the HIV-infected
subpopulations who are at an increased risk for
osteopenia/osteoporosis are needed to determine the
best management of this clinical condition.
Multiple factors are involved in the pathogenesis of
altered bone homeostasis in HIV infection [3]. Osteo-
penia was initially attributed to HAART, especially to
regimens that contain protease inhibitors or tenofovir
[3]. HIV infection was postulated as a possible cause be-
cause HIV-encoded proteins were demonstrated to
modulate osteoblast development/function and osteo-
clast differentiation [4-6].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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younger HIV-infected individuals compared with the
HIV-negative population suggests that these diseases
could be the result of premature aging [7]. Similar to
other age-related diseases, osteoporosis is initiated and/
or worsened by chronic, systemic low-grade inflamma-
tory activity that leads to long-term tissue damage [8].
HIV-infected patients on HAART, despite full virologic
control, exhibit a hyperactivated immune profile that is
characterized by increased circulating pro-inflammatory
cytokines and reduced naïve/central memory T-cell
subsets in favor of activated/senescent phenotypes
[9-11]. These immunological alterations are similar to
those that have been observed in the HIV-uninfected
elderly and may contribute to the premature clinical
aging of HIV-infected patients, even in the context of
virologically suppressive therapy [12-14].
Furthermore, patients with chronic HIV infection dis-
play significantly increased plasma levels of interleukin-7
(IL-7), which is a type-1 stromally produced cytokine
that has been demonstrated to promote osteoclast ac-
tivity by upregulating T-cell-derived osteoclastogenic
cytokines [15-17]. A substantial reduction in IL-7R-
expressing T-cells with impairment of IL-7-mediated sig-
naling has been described [18].
Despite the evidence of a pathogenetic role of T-cell
activation and IL-7/IL-7R dysfunction that favors osteo-
clast formation and bone resorption under inflammatory
conditions [19,20], no studies have specifically addressed
the correlations between the HIV-related peripheral im-
mune phenotype and the pathogenesis of bone metabol-
ism disorders.
Therefore, we aimed to evaluate whether HIV-infected
patients with impaired BMD are characterized by an
activated/senescent immune phenotype and a pro-
inflammatory cytokine milieu in peripheral blood, which
may suggest that there are specific immune pathogenetic
pathway(s) that are involved in HIV-related bone
disorders. The identification of immunological marker(s)
that are associated with impaired BMD could provide
additional tools for the early detection of HIV-infected
subpopulations who are at an increased clinical risk of
osteopenia/osteoporosis and who would greatly benefit
from specific screening programs and therapeutic
strategies.
Patients and methods
Patient enrollment
From June 2006 to July 2008, a cross-sectional study was
conducted at the Clinic of Infectious Diseases at “San
Paolo” Hospital, University of Milan. All patients provided
informed consent. We consecutively enrolled HIV-positive
patients of both sexes who were naïve or on stable
HAART for at least 12 months and who underwent BMDanalysis by dual-energy X-ray absorptiometry (DXA) and
PBMC/plasma collection for immunologic analyses. The
exclusion criteria were concomitant opportunistic infec-
tions and/or primary HIV infection.
Bone mineral density
BMD at the lumbar spine (LS) and femoral neck (FN)
was measured by DXA on a QDR 4500 bone densitom-
eter using Hologic Discovery W. T-scores, which com-
pare subjects with young individuals of the same sex and
race, were derived from the National Health and Nutri-
tion Examination Survey (NHANES III). According to
WHO criteria, osteopenia was defined by T-scores at the
LS and/or FN that were < −1 SD and ≥ −2.5; osteoporosis
was defined by T-scores < −2.5 [21]. For pre-menopausal
women and men younger than 50 years of age z-
score < −1 was used for osteopenia diagnosis, and z-
score < −2 for osteoporosis [22,23].
Immunophenotypic analysis
All of the immunophenotypic assays were performed on
frozen samples. The following fluorochrome-labeled
mAbs were used: HLA-DR-FITC, CD38–PE, CD4-
PerPC-Cy5.5, and CD8-PerPC-Cy5.5; CD4-Pcy7, CD8-
Pcy5, and CD127-PE (BD Biosciences, San Jose, California,
USA); and CD57-FITC, CD28-PE, CD8-Pcy5, and CD4-
Pcy7 (Beckman Coulter, Hialeah, FL). The following
combinations were used: CD4/CD127, CD8/CD127, CD4/
CD38/HLA-DR, CD8/CD38/HLA-DR, and CD4/CD8/
CD28/CD57. The analysis was conducted using a Cytomics
FC500 instrument (Beckman Coulter, Hialeah, FL).
Quantification of IL-7Rα mRNA by real-time PCR in CD4+
and CD8+ T-cells
Following the isolation of PBMCs from peripheral blood
(Ficoll Histopaque, Biochrom AG Seromed, Milan, Italy),
CD4+ and CD8+ lymphocytes were separated with mag-
netic beads (Microbeads, Miltenyi, Bologna, Italy).
Total RNA was isolated from CD4+ and CD8+ T-cells
using the commercially available RNeasy Micro Kit
(Qiagen, Milan, Italy) according to the manufacturer’s
instructions. Potential genomic DNA contamination
was removed by incubating the RNA for 15 min at
room temperature with RNase-free DNase I (Invitrogen,
Carlsbad, CA, USA). From each sample, a variable amount
of total RNA was reverse transcribed into cDNA using the
SuperScript™ III First-Strand Synthesis System (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
instructions under the following conditions: 25°C for
10 min, 50°C for 30 min and 85°C for 5 min. After RNase
H was added to eliminate potential RNA contamination, a
final incubation was conducted at 37°C for 20 min.
IL-7Rα mRNA detection was performed using an Assay-
on-Demand Kit (Assay ID Hs00233682_m1, Applied
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TFRC (Assay ID Hs99999911_m1, Applied Biosystems)
was used as a control as previously described [18].
Pro-inflammatory and osteoclastogenic cytokines
IL-7 and TNF-α plasma concentrations were evaluated
by ELISA (Quantikine HS Human IL-7 and Human
TNF-α, R&D Systems, Milan, Italy) according to the
manufacturer’s instructions. The plasma concentrations
of nuclear factor kappa-B ligand (RANKL) and its sol-
uble receptor antagonist osteoprotegerin (OPG) were
measured by ELISA (Human Soluble RANKL Total
ELISA, BioVendor, Czech Republic, and Quantikine HS
Human OPG, R&D Systems, Milan, Italy) according to
the manufacturer’s instructions.
Statistical analysis
The continuous variables were represented as the me-
dian and IQR; the categorical parameters as the absolute
numbers and percentage. The differences between
LBMD and NBMD patients were assessed by Mann–
Whitney test and Pearson’s chi-squared test (continuous
parameters), and by Mann–Whitney test and Fisher’sTable 1 Characteristics of the study population and analysis o
parameters between low bone mineral density (LBMD) patien
(NBMD) patients (T-score ≥ −1)
TOT
Demographic characteristics
male
mean age (IC 95%) 4
mean BMI (IC 95%) 23.
HIV-related parameters
AIDS diagnosis
time from HIV diagnosis (IC 95%) 7.8 y
mean CD4 nadir (IC 95%) 26
(
mean current CD4 (IC 95%) 50
(
mean CD4/CD8 ratio (IC 95%) 0.7
co-infection with viral hepatitis
HCV Ab positivity
HBsAg positivity
naïve patients
mean time of HAART exposure (IC 95%) 4.6 y
type of HAART
TDF-based backbone
PI-based
NNRTI-based
undetectable viremia (HIV-RNA <40 UI/mL) (in patients on HAART)
§p, comparison between LBMD and NBMD patients by *Pearson’s chi-squared test aexact test (categorical parameters). Two multivariate
logistic regression models were established to identify
potential predictors of osteopenia/osteoporosis: we sep-
arately analyzed the association between immunological
markers on CD4+ T cells (model 1) and CD8+ T cells
(model 2) in patients with low BMD. We established
two models to assess whether low BMD was indepen-
dently influenced by the phenotype of circulating CD4+
and CD8+ T-cell subpopulations. Each model was
adjusted for demographic and HIV-related variables
(age, sex, BMI, hepatitis coinfection, CD4+ count, time
on HAART). All of the statistical analyses were per-
formed using SPSS software (version 18.01, SPSS). All of
the tests were 2-sided, and p≤0.05 was considered to be
a cut-off for statistical significance.
Results
Demographics, HIV-related parameters and bone mineral
density of the study population
A total of 78 HIV-infected patients were recruited.
The patient demographics are represented in Table 1.
Regarding HIV infection, patients were characterized by a
mean CD4+ count of 507 cell/mm3; most of the patientsf the demographic characteristics and HIV-related
ts (T-score < −1) and normal bone mineral density
AL (n = 78) LBMD (n = 55) NBMD (n = 23) P§
68% 66.7% 69.6% 0.80*
6 (43–48) 46 (43–48) 45 (40–50) 0.81
4 (22.5-24.3) 23.4 (22.5-24.9) 24.6 (23.0-26.2) 0.16
22% 23% 17% 0.54*
ears (6.3-9.3) 7.8 years (5.8-9.8) 7.8 years (5.5-10.4) 0.99
8 cell/mm3
226–310)
266 cell/mm3
(214–317)
265 cell/mm3
(195–336)
0.98
7 cell/mm3
437–577)
490 cell/mm3
(400–579)
512 cell/mm3
(407–617)
0.77
(0.59-0.80) 0.7 (0.54-0.77) 0.8 (0.56-1.02) 0.25
10% 12% 4% 0.26**
5% 3% 8% 0.63**
26% 28% 17% 0.31**
ears (3.4-5.9) 4.0 years (2.6-5.5) 6.2 years (3.8-8.7) 0.13
0.40*
53% 54% 53%
33% 34% 35%
37% 33% 48%
92% 88% 94% 1.00*
nd **Fisher’s exact test.
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mean time of 6.7 years of HAART exposure. In addition,
the enrolled patients exhibited a low prevalence of the
common risk factors for osteoporosis.
DXA analysis was performed on all 78 of the patients
who were enrolled in the study according to the inclu-
sion criteria: 23/78 patients (30%) exhibited a BMD
within a normal range at both sites, 47/78 patients
(60%) had a reduction in BMD that indicated osteopenia
and 8/78 patients (10%) had a BMD reduction that
indicated osteoporosis.
Patients who were characterized by a low BMD, including
both osteopenic and osteoporotic patients (LBMD: defined
by a T-score or z-score <−1), were comparable to normal
BMD patients (NBMD: defined by a T-score or z-score ≥ −1)
according to the demographic characteristics and com-
mon HIV-related parameters, such as the CD4+ nadir and
current value, time from HIV diagnosis, HAART
exposure and type of HAART, as represented in Table 1.
HIV-positive patients with low BMD display a
hyperactivated peripheral T-cell phenotype
We compared CD4+ and CD8+ T-cell activation in a sub-
group of 62 patients for whom viable PBMCs were available
(21 NBMD patients and 41 LBMD patients) (Figure 1).
According to the analysis of HLADR expression,
patients with LBMD demonstrated an increased fre-
quency of activated CD4+ T-cells (HLADR + CD4+
24.3% [IQR = 16.7%-34.7%] in LBMD patients and 18.6%
[IQR = 6.3%-28.2%] in NBMD patients; p = .03) and CD8+
T-cells (HLADR +CD8+ 38.2% [IQR = 29.8%-53.2%] in
LBMD patients and 25.3% [IQR = 18.75%-36.15%] in
NBMD patients, p = .002) (Figures 1A and B).
No differences in the expression of CD38 on CD4+
and CD8+ T-cells were observed between the LBMD
and NBMD patients (CD38 + CD4+ 53.5% [IQR = 39.2%-
68.55%] in LBMD patients and 59.9% [IQR = 36.2%-
68.0%] in NBMD patients, p = .90; CD38 + CD8+ 35.3%
[IQR = 24.6%-44.0%] in LBMD patients and 32.6% [IQR
= 23.0%-46.9%] in NBMD patients, p = .92) (Figures 1C
and D). Similarly, no significant differences were ob-
served in the co-expression of CD38 and HLADR on
CD4+ and CD8+ T-cells among the LBMD and NBMD
patients (HLADR + CD38 + CD4+ 12.9% [IQR = 6.4%-
16.8%] in LBMD patients and 8.9% [IQR = 3.6%-17%] in
NBMD patients, p = .16; HLADR + CD38 + CD8+ 17.2%
[IQR = 10.9%-22.2%] in LBMD patients and 16.2%
[IQR = 7.7%-18.4%] in NBMD patients, p = .17) (Figures1E
and F).
We observed an association between LBMD and
increased CD4+ and CD8+ T-cell activation; therefore,
we investigated whether a similar finding could be
obtained in the subgroup of patients who were virologically
suppressed under HAART. In 57/78 patients who wereon stable virologically suppressive HAART (HIV RNA< 50
cp/ml), the patients with LBMD displayed increased CD8+
T-cell activation (HLADR+CD8+ 36.6% [IQR = 30.7%-
51.6%] in LBMD patients and 29.6% [IQR = 17.7%-36.1%]
in NBMD patients, p = .008) but no significant differences
in CD4+ T-cell activation (HLADR+CD4+ 23.1% [IQR =
16.7%-36.4%] in LBMD patients and 19.7% [IQR = 10.4%-
28.1%] in NBMD patients; p = .08).HIV-positive patients with low BMD exhibit a contraction
of the central memory CD127 + CD8+ T-cell pool
The loss of IL-7Rα (CD127) expression on CD8+ T-cells
defines a population at a terminal state of differentiation
and has been associated with a higher level of T-cell ac-
tivation in the course of HIV infection [24]; therefore,
we compared CD127 expression on the peripheral T-
cells of LBMD patients vs. NBMD patients. The analysis
were performed in 78 patients, no differences in the pro-
portion of CD4+ T-cells that expressed CD127 were
observed between LBMD and NBMD patients (CD127 +
CD4+ T-cells 17% [IQR = 10.2%-24%] and 19% [IQR =
15%-27%], respectively, p = .16) (Figure 1G). Interest-
ingly, patients with LBMD demonstrated a non signifi-
cant trend toward a reduced frequency of CD8+ T-cells
that expressed CD127 compared with NBMD patients:
the proportion of CD127 + CD8+ T-cells was 13% (IQR =
8.2%-17%) in LBMD patients and 14% (IQR = 10%-22%)
in NBMD patients (p = .06) (Figure 1H).
After observing a trend toward a lower percentage of
CD127 + CD8+ T-cells in patients with LBMD, we
investigated whether the decreased expression of CD127
on the CD8+ T-cell surface corresponded to a reduced
production of CD127. We measured IL-7Rα mRNA in
CD8+ T-cells from a subgroup of 22 unselected patients
(7 NBMD patients and 15 LBMD patients). The patients
who were affected by LBMD demonstrated IL-7Rα
mRNA levels in CD8+ T-cells that were comparable to
patients with NBMD (median copies of IL-7Rα mRNA/
100 ng TFRC: 753 [IQR = 207-1,014] in LBMD patients
and 1,037 [IQR = 581-3,615] in NBMD patients, p = .14).HIV-positive patients with low BMD display a peripheral
cytokine milieu comparable to patients with normal BMD
After observing a hyperactivated T-cell phenotype in
LBMD patients, we evaluated whether these patients were
characterized by a pro-inflammatory and osteoclastogenic
cytokine pattern in peripheral blood (TNF-α, IL-7, RANKL,
and OPG). Analysis were performed on a subgroup of 42
patients (14 NBMD and 28 LBMD), LBMD patients
displayed no differences in median TNF-α plasma levels
compared with NBMD patients (4.9 pg/mL [IQR = 1.7-
15.8] and 2.4 pg/mL [IQR = 1.6-16.4], respectively, p = .48)
or in median IL-7 plasma levels (6.5 pg/mL [IQR = 2.4-
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Figure 1 An immunophenotypic analysis of peripheral blood T-cell activation was performed on sixty-two patients (41 LBMD patients
and 21 NBMD patients). Patients with LBMD are shown in the circles, and patients with NBMD are shown in the triangles. The median percentage
of HLADR + on CD4+ (A) and CD8+ (B) T-cells. The median percentage of CD38+ on CD4+ (C) and CD8+ (D) T-cells. The median percentage of
HLADR + CD38+ on CD4+ (E) and CD8+ (F) T-cells. The bars correspond to the IQR. The expression of CD127 on CD4+ and CD8+ T-cells was
evaluated for all seventy-eight patients. The median percentage of CD127 + CD4+ (G) and CD8+ (H) T-cells in PBMCs. The bars correspond to the IQR.
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NBMD patients, p = .91).
Similarly, the analysis of osteoclastogenic cytokines
showed no differences in median RANKL plasma levelsbetween LBMD and NBMD patients (5,872 pg/mL [IQR =
2,823-10,259] in LBMD patients and 8,438 pg/mL [IQR =
6,421-11,766] in NBMD patients, p = .08) or in median
plasma OPG levels (550 pg/mL [IQR = 420-1,001] in
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NBMD patients, p = .97).
Analysis of peripheral immune-senescent CD4+ and CD8+
T-cell patterns
Based on the phenotype data that indicated high activa-
tion in LBMD patients, we investigated the immune sen-
escent pattern of CD4+ and CD8+ T-cells in LBMD
patients and NBMD patients according to the expression
of CD28 and CD57. T-cell immune senescence was
analyzed in the same subgroup of 62 patients for whom
T-cell activation data were available.
Unexpectedly, we observed a higher frequency of
CD28 + CD4+ T-cells in LBMD patients compared with
NBMD patients (94.2% [IQR = 85.5%-97.1%] in LBMD
patients and 87.8% [IQR = 72.4%-94.1%] in NBMD
patients, p = .03) and a lower frequency of antigen-
experienced CD28-CD4+ T-cells in LBMD patients
compared with NBMD patients (5.8% [IQR = 1.9%-
14.2%] in LBMD patients and 12.1% [IQR = 4.8%-27.4%]
in NBMD patients, p = .04) (Figure 2A). No differences
in CD28 expression on CD8+ T-cells were observed be-
tween the patient groups (CD28 + CD8+ 34.3% [IQR =
23.6%-55.6%] in LBMD patients and 35.5% [IQR =
22.6%-52.8%] in NBMD patients, p = .92; CD28-CD8+ T-
cells 65.5% [IQR = 22.6%-55.6%] in LBMD patients and
64.4% [IQR = 42.6%-77%] in NBMD patients, p = .89)
(Figure 2B).
The analysis of CD28 and CD57 co-expression on T-
lymphocytes resulted in different phenotypes according
to bone mineral density (Figure 2). There were no
differences in the frequencies of senescent CD28-CD57 +
CD4+ T-cells (3.4% [IQR = 0.5%-8.5%] in LBMD patients
and 3.5% [IQR = 1.3%-14%] in NBMD patients, p = .24)
(Figure 2C); however, LBMD patients displayed higher
CD28 + CD57-CD4+ T-cells (85.4% [IQR = 74.7%-93.8%]
in LBMD patients and 75.0% [IQR = 57.8%-89.6%] in
NBMD patients, p = .04) and lower CD28-57-CD4+ T-
cells (2.4% [IQR = 1.1%-4.6%] in LBMD patients and 4.5%
[IQR = 2.5%-13.1%] in NBMD patients, p = .02) (Figure 2C).
No differences in CD28 + CD57 + CD4+ T-cells were
observed (5.1% [IQR = 1.9%-12.6%] in LBMD patients
and 5.6% [IQR = 2.9%-15.2%] in NBMD patients, p = .56)
(Figure 2C).
Similar CD28/CD57-expressing profiles were observed
with CD8+ T-cells. LBMD patients exhibited a lower fre-
quency of CD28-CD57-CD8+ T-cells (18.2% [IQR = 13%-
28.1%] in LBMD patients and 28.4% [IQR = 18.9%-36.7%]
in NBMD patients, p = .02), whereas no differences in
any other subpopulations were observed (CD28 + CD57-
CD8+ 28.8% [IQR = 15.7%-47.2%] in LBMD patients and
26.1% [IQR = 12.4%-40.4%] in NBMD patients, p = .42;
CD28 + CD57 + CD8+ 7.0% [IQR = 4.3%-10.7%] in LBMD
patients and 8.7% [IQR = 3.3%-17.8%] in NBMD patients,p = .49; CD28-CD57+ 37.4% [IQR = 23.6%-52.5%] in
LBMD patients and 33.2% [IQR = 22.8%-45.4%] in NBMD
patients, p = .33) (Figure 2F).
CD4+ and CD8+ T-cell activation is a risk factor that is
independently associated with low BMD
A hyperactivated immune pattern is associated with low
BMD; therefore, we investigated the predictive role of
immunological parameters after controlling for potentially
confounding demographic and HIV-related parameters
(Table 2). Interestingly, CD4+ and CD8+ T-cell activation
was independently associated with low BMD (for each
point increase in percentage of HLADR+CD4+: AOR=
1.08, CI 95%, 1.01-1.15, p = .02 and for each point in-
crease in percentage of HLADR+CD8+: AOR= 1.06;
CI 95%, 1.01-1.11, p = .01). The expression of CD28 on
CD4+ T-cells was associated with low BMD at a limit of
statistical significance (for each point increase in percentage
of CD28 +CD4+: AOR= 1.07; CI 95%, 1.00-1.13, p = .04).
As shown in Table 2, no other variables were inde-
pendently associated with pathologic DXA.
Discussion
The pathogenesis of bone metabolism disorders in
HIV-infected patients has been attributed to either HIV
or several antiretroviral drugs, such as tenofovir or prote-
ase inhibitors [4-6,25]. Recently, a pathogenetic model
attributed the early onset of osteopenia/osteoporosis to
the generalized inflammation and immunosenescence that
characterizes HIV-infected populations, including in the
context of virologically suppressive HAART [12,13].
In this study, we investigated whether HIV-infected
patients who were affected by osteopenia/osteoporosis
displayed a circulating T-cell immune phenotype that
indicated hyperactivation and premature senescence.
In HIV-infected patients who were affected by low
BMD, we demonstrated the following: 1) higher peripheral
T-cell activation, 2) less pro apoptotic CD28-negative
CD4+ T-cells despite no changes in senescent CD28-57+
T-cells, and 3) a highly activated T-cell phenotype as an
independent predictor of impaired BMD.
Elevated immune activation is the main pathogenetic
mechanism that is involved in HIV infection with
and without HAART: it is predictive of the clinical
progression to AIDS [24] and has recently been
demonstrated to be associated with the emergence of
co-morbidities, such as cardiovascular disease and in-
tima thickness [26,27].
For the first time, our study demonstrates the involve-
ment of HIV-related immune activation in the pathogen-
esis of bone co-morbidities. The immune phenotype in
the peripheral blood of patients with pathological BMD
is characterized by a higher frequency of activated T-
cells compared with patients with normal BMD. In
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Figure 2 The immune senescent pattern of CD4+ and CD8+ T-cells. Patients with LBMD are shown in the circles, and patients with NBMD are
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CD28+ and CD28-CD8+ T-cells. C) The median percentage of CD4+ T-cell sub-populations as defined by CD28 and CD57 co-expression (CD28 +
CD57-, CD28 + CD57+, CD28-CD57-, and CD28-CD57+). D) and E) are representative plots that show the senescence markers (CD57 and CD28) on the
CD4+ T-cells of patients with LBMD (D) and patients with NBMD (E). The data were compensated and analyzed using CXP 2.2 software (Beckman-
Coulter). F) The median percentage of CD8+ T-cell sub-populations as defined by CD28 and CD57 co-expression (CD28 + CD57-, CD28 + CD57+,
CD28-CD57-, and CD28-CD57+). G) and H) are representative plots that show the senescence markers (CD57 and CD28) on the CD8+ T-cells of
patients with LBMD (G) and patients with NBMD (H). The data were compensated and analyzed using CXP 2.2 software (Beckman-Coulter).
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low BMD was confirmed in patients on stable HAART
with full virological suppression. Interestingly, in the multi-
variate logistic regression analysis that was adjusted for
demographics and HIV- and HAART-related parameters, ahigher frequency of activated CD4+/CD8+ T-cells was an
independent predictor of osteopenia/osteoporosis.
Similarly, we observed that the immune phenotype in
the peripheral blood of patients with impaired BMD was
characterized by a non significant trend toward lower
Table 2 Predictors of osteopenia/osteoporosis
Model 1* Model 2^
AOR CI 95% p AOR CI 95% p
sex (male) 1.11 0.24-5.17 .9 0.90 0.21-3.82 .9
age (for each additional year) 1.03 0.97-1.10 .3 1.01 0.95-1.07 .7
BMI (for each additional point) 1.00 0.99-1.00 .9 1.00 0.99-1.00 .8
hepatitis co-infection 1.39 0.15-12.7 .8 1.84 0.25-13.4 .5
CD4+ nadir (for 50 cells or more) 1.08 0.88-1.32 .4 1.04 0.87-1.24 .7
time on HAART (for each additional year) 0.92 0.80-1.05 .2 0.93 0.81-1.07 .3
HLA-DR + CD4+ (for each additional %) 1.08 1.01-1.15 .02
CD28 + CD4+ (for each additional %) 1.06 1.0-1.13 .04
HLA-DR + CD8+ (for each additional %) 1.06 1.01-1.11 .01
CD127 + CD8+ (for each additional %) 0.94 0.83-1.06 .3
*Model 1: a multivariate logistic regression was performed to explore the association between CD4+ activation and senescence with low BMD, adjusting for
demographic and HIV-related parameters. ^Model 2: a multivariate logistic regression was performed to explore the association between activated and central
memory CD8+ T cells with low BMD after correction for demographic and HIV-related parameters.
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with patients with normal BMD.
In HIV/AIDS, the expansion of CD8+ T-cells that lack
CD127 has been consistently described [28-31] as a
functional status of terminal differentiation [32,33] and
has been attributed to chronic antigenic stimulation.
Thus, higher T-cell activation with contraction in the
compartment of central memory CD127 + CD8+ T-cells
in patients who are affected by osteopenia/osteoporosis
may suggest increased T-cell turnover with skewed mat-
uration of CD8+ T-cells.
Osteoporosis is not typically considered to be an
immune-mediated disorder; however, recent data have
indicated an overlapping pathway between bone phys-
iology and the biology of inflammation that involves the
T-lymphocyte compartment. Activated T-cells affect bone
physiology by producing RANKL and pro-inflammatory
cytokines (e.g., IL-1 and TNF-α), which promote osteo-
clast activity [34] and stimulate stromal cells to produce
osteoclastogenic IL-7 [15].
Thus, after observing a hyperactivated circulating T-
cell immune profile in patients with bone metabolism
disorders, we investigated the pro-inflammatory osteo-
clastogenic cytokine milieu.
Despite a non significant trend toward a higher level of
TNF-α in patients with low BMD, the levels of IL-7 and
osteoclastogenic cytokines were comparable among LBMD
and NBMD subjects. More than 70% of the patients were
on long-term HAART; therefore, this finding is in agree-
ment with recent data that demonstrated an increase in the
osteoclastogenic cytokines RANKL and TNF-α within the
first weeks of therapy with no additional surges [35]. More-
over, the DXA analysis provides a static picture of BMD;
however, the cytokine milieu depicts the current balance of
bone remodeling processes and may be influenced by many
factors, mainly the effect of protease inhibitors [36].We next determined whether these LBMD patients
were characterized by an immune senescent pattern in
peripheral blood.
Despite increased activation, no differences in the pro-
portion of senescent (CD28-CD57+) CD4+ and CD8+
T-cells were observed in patients with impaired BMD
compared with patients with normal BMD.
Unexpectedly, patients with impaired BMD displayed
a circulating CD4+ T-cell immune phenotype that was
enriched for CD28-expressing cells at the disadvantage
of the highly differentiated CD28-negative pool. Interest-
ingly, this CD4+ immune phenotype was independently
associated with osteopenia/osteoporosis in the multivari-
ate logistic regression analysis.
The downregulation of CD28 has been extensively
described in CD8+ T-cells as a hallmark of chronic anti-
genic stimulation, even in the course of HIV infection.
With each repetitive stimulation/proliferation round,
CD28 expression is irreversibly downregulated on the
CD8+ surface, leading to the accumulation of antigen-
experienced (CD28-negative) CD8+ T-cells with shortened
telomeres, impaired proliferative ability and decreased sus-
ceptibility to apoptosis.
In addition, the loss of CD28 is observed in CD4+ T-
cells during chronic immune activation but at a signifi-
cantly lower rate than CD8+ [37]. Despite the evidence
of CD28-CD8+ T-cell accumulation in HIV infection,
there are no data on CD28-CD4+ T-cell accumulation.
In our study, patients who were affected by
osteopenia/osteoporosis displayed high levels of T-cell
activation and a reduction in the CD28-CD4+ T-cell
pool. As a possible explanation for this finding, Vivar
et al. recently demonstrated that CD28-negative T cells,
although senescent, display a proapoptotic phenotype, as
suggested by high Fas and decreased IL7Rα and Bcl-2 ex-
pression [38]. These T-cells are highly susceptible to
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HIV replication and generalized immune activation.
Therefore, the contraction of the CD28-negative CD4+ T-
cell pool that we observed in patients with bone disorders
may have resulted from increased activation-induced
apoptosis.
The main limitation to this study is the population
that was enrolled, which included both HIV-infected
patients who were naïve to antiretroviral therapy and
patients undergoing HAART. Many factors may have
played a role in the pathogenesis of osteoporosis in these
two distinct populations because several antiretroviral
medications may directly decrease bone mineral density
and act as confounding factors.
Conclusion
In conclusion, to our knowledge, this is the first study to
provide evidence of an association between osteopenia/
osteoporosis and heightened T-cell activation in HIV-
infected patients. These results may have important clin-
ical implications in research focused on the assessment
of subpopulations of HIV-infected patients who are at
increased risk of osteopenia/osteoporosis. Moreover, our
data highlight the role of immune activation in the
pathogenesis of HIV-related bone metabolism disorders
and support the need for additional longitudinal studies
to investigate the role of biomarkers of immune activa-
tion as predictors of noninfectious co-morbidities.
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